P. Sandy

Most-cited papers

1. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

   D. Barbie, P. Tamayo, J. Boehm, S. Kim +31 more

   2009Nature3,493 citations Open access

   Semantic Scholar

   Save

2. Targeting MYC dependence in cancer by inhibiting BET bromodomains

   J. Mertz, Andrew R. Conery, Barbara Bryant, P. Sandy +4 more

   2011Proceedings of the National Academy of Sciences of the United States of America1,134 citations Open access

   Semantic Scholar

   Save

3. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

   C. Scholl, S. Fröhling, Ian F. Dunn, A. Schinzel +14 more

   2009Cell574 citations Open access

   Semantic Scholar

   Save

4. Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1

   M. Gostissa, Arnd Hengstermann, V. Fogal, P. Sandy +3 more

   1999EMBO Journal558 citations Open access

   Semantic Scholar

   Save

5. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer

   K. Vasudevan, D. Barbie, M. Davies, Rosalia Rabinovsky +30 more

   2009Cancer Cell548 citations Open access

   Semantic Scholar

   Save

6. Regulation of p53 activity in nuclear bodies by a specific PML isoform

   V. Fogal, M. Gostissa, P. Sandy, P. Zacchi +6 more

   2000EMBO Journal410 citations Open access

   Semantic Scholar

   Save

7. Regulation of leukemia-initiating cell activity by the ubiquitin ligase FBXW7

   B. King, Thomas Trimarchi, L. Reavie, Lu-Yao Xu +10 more

   2013Cell319 citations Open access

   Semantic Scholar

   Save

8. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.

   B. Albrecht, Victor S. Gehling, M. Hewitt, Rishi G. Vaswani +23 more

   2016Journal of Medicinal Chemistry183 citations Open access

   Semantic Scholar

   Save

9. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

   M. Ceribelli, Priscilla N. Kelly, A. Shaffer, G. Wright +15 more

   2014Proceedings of the National Academy of Sciences of the United States of America183 citations Open access

   Semantic Scholar

   Save

10. Mammalian RNAi: a practical guide.

    P. Sandy, Andrea Ventura, T. Jacks

    2005BioTechniques160 citations Open access

    Semantic Scholar

    Save

11. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.

    Shivani Garapaty-Rao, C. Nasveschuk, A. Gagnon, E. Chan +11 more

    2013Chemistry and Biology153 citations Open access

    Semantic Scholar

    Save

12. Glycogen Synthase Kinase-3β Regulates NF-κB1/p105 Stability*

    F. Demarchi, C. Bertoli, P. Sandy, C. Schneider

    2003Journal of Biological Chemistry143 citations Open access

    Semantic Scholar

    Save

13. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

    Andrew R. Conery, Richard C. Centore, A. Neiss, Patricia J. Keller +11 more

    2016eLife117 citations Open access

    Semantic Scholar

    Save

14. The Cell Cycle-regulated Protein Human GTSE-1 Controls DNA Damage-induced Apoptosis by Affecting p53 Function*

    M. Monte, R. Benetti, G. Buscemi, P. Sandy +2 more

    2003Journal of Biological Chemistry104 citations Open access

    Semantic Scholar

    Save

15. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

    A. Moros, V. Rodríguez, I. Saborit-Villarroya, A. Montraveta +9 more

    2014Leukemia103 citations

    Semantic Scholar

    Save

16. Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation

    Cristina Cellurale, G. Sabio, Norman J. Kennedy, Madhumita Das +4 more

    2011Molecular and Cellular Biology102 citations Open access

    Semantic Scholar

    Save

17. Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes.

    C. Dillon, P. Sandy, A. Nencioni, S. Kissler +2 more

    2005Annual Review of Physiology102 citations

    Semantic Scholar

    Save

18. Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.

    Victor S. Gehling, M. Hewitt, Rishi G. Vaswani, Y. Leblanc +20 more

    2013ACS Medicinal Chemistry Letters95 citations Open access

    Semantic Scholar

    Save

19. Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis.

    Raffaella Spagnuolo, M. Corada, F. Orsenigo, L. Zanetta +6 more

    2004Blood85 citations

    Semantic Scholar

    Save

20. The PDZ Protein Tax-interacting Protein-1 Inhibits β-Catenin Transcriptional Activity and Growth of Colorectal Cancer Cells*

    Mutsumi Kanamori, P. Sandy, S. Marzinotto, R. Benetti +4 more

    2003Journal of Biological Chemistry83 citations Open access

    Semantic Scholar

    Save

21. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK 1

    D. Barbie, P. Tamayo, Jesse S. Boehm, So Young Kim +31 more

    201273 citations

    Semantic Scholar

    Save

22. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition*

    Srimoyee Ghosh, Alexander M. Taylor, M. Chin, Hon-Ren Huang +32 more

    2016Journal of Biological Chemistry72 citations Open access

    Semantic Scholar

    Save

23. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability.

    F. Demarchi, C. Bertoli, P. Sandy, C. Schneider

    2003Journal of Biological Chemistry66 citations

    Semantic Scholar

    Save

24. p53 is involved in the p120E4F-mediated growth arrest

    P. Sandy, M. Gostissa, V. Fogal, L. de Cecco +4 more

    2000Oncogene58 citations

    Semantic Scholar

    Save

25. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

    C. Wong, S. Laddha, L. Tang, E. Vosburgh +6 more

    2014Cell Death and Disease54 citations Open access

    Semantic Scholar

    Save

26. Identification of potent, selective KDM5 inhibitors.

    Victor S. Gehling, S. Bellon, J. Harmange, Y. Leblanc +17 more

    2016Bioorganic & Medicinal Chemistry Letters40 citations Open access

    Semantic Scholar

    Save

27. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.

    Terry D. Crawford, Steffan Vartanian, A. Côté, S. Bellon +20 more

    2017Bioorganic & Medicinal Chemistry Letters36 citations Open access

    Semantic Scholar

    Save

28. Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains.

    Alexander M. Taylor, Rishi G. Vaswani, Victor S. Gehling, M. Hewitt +19 more

    2016ACS Medicinal Chemistry Letters25 citations Open access

    Semantic Scholar

    Save

29. 495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas

    Judy S. Wang, G. Falchook, Salah Nabhan, Meghana M. Kulkarni +5 more

    2021Journal for ImmunoTherapy of Cancer24 citations Open access

    Semantic Scholar

    Save

30. Development of methyl isoxazoleazepines as inhibitors of BET.

    M. Hewitt, Y. Leblanc, Victor S. Gehling, Rishi G. Vaswani +18 more

    2015Bioorganic & Medicinal Chemistry Letters21 citations

    Semantic Scholar

    Save

31. GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).

    Terry D. Crawford, J. Audia, S. Bellon, D. Burdick +30 more

    2017ACS Medicinal Chemistry Letters20 citations Open access

    Semantic Scholar

    Save

32. A Transient Transgenic RNAi Strategy for Rapid Characterization of Gene Function during Embryonic Development

    B. Bjork, Y. Fujiwara, S. Davis, Haiyan Qiu +5 more

    2010PLoS ONE18 citations Open access

    Semantic Scholar

    Save

33. GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.

    Alexander M. Taylor, C. Bailey, Lisa D. Belmont, R. Campbell +26 more

    2022Journal of Medicinal Chemistry17 citations Open access

    Semantic Scholar

    Save

34. P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity

    D. McHale, L. Francisco-Anderson, P. Sandy, S. Shariffudin +18 more

    202016 citations Open access

    Semantic Scholar

    Save

35. RNA interference for the identification of disease-associated genes.

    A. Nencioni, P. Sandy, C. Dillon, S. Kissler +2 more

    2004Current opinion in molecular therapeutics (Print)14 citations

    Semantic Scholar

    Save

36. Gas 1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis

    Raffaella Spagnuolo, M. Corada, F. Orsenigo, L. Zanetta +6 more

    200414 citations

    Semantic Scholar

    Save

37. Epi-allelic Erk1 and Erk2 knockdown series for quantitative analysis of T cell Erk regulation and IL-2 production.

    Lucia Wille, Melissa L. Kemp, P. Sandy, Christina L. Lewis +1 more

    2007Molecular Immunology11 citations Open access

    Semantic Scholar

    Save

38. Monoclonal microbial EDP1503 to induce antitumor responses via gut-mediated activation of both innate and adaptive immunity.

    H. Gardner, S. Kashyap, H. Ponichtera, P. Sandy +8 more

    2019Journal of Clinical Oncology7 citations

    Semantic Scholar

    Save

39. Abstract PS11-27: A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer

    Loise Francisco-Anderson, Shamira Shariffudin, H. Gardner, P. Sandy +13 more

    20214 citations

    Semantic Scholar

    Save

40. Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

    Andrew R. Conery, Richard C. Centore, A. Neiss, Patricia J. Keller +11 more

    2016eLife4 citations Open access

    Semantic Scholar

    Save

41. Abstract LB-237: In vitro and in vivo characterization of CPI-267203, a potent Inhibitor of bromodomain-containing proteins

    E. Normant, R. Cummings, S. Bellon, Christopher Bailey +8 more

    20124 citations

    Semantic Scholar

    Save

42. Assignment1 of the E1A-regulated transcription factor E4F gene (E4F1) to human chromosome band 16p13.3 by in situ hybridization and somatic cell hybrids

    S. Saccone, P. Sandy, G. Meroni, M. Gostissa +2 more

    1998Cytogenetic and Genome Research3 citations

    Semantic Scholar

    Save

43. A novel approach for first‐in‐human dose selection using population dose–response modelling to find a minimum anticipated biological effect level

    Lin Yuan, Meghana Kulkarni, Evan L. Chiswick, Cheryl Koh +11 more

    2025British Journal of Clinical Pharmacology2 citations

    Semantic Scholar

    Save

44. Corrigendum to “Development of methyl isoxazoleazepines as inhibitors of BET” [Bioorg. Med. Chem. Lett. 25/9 (2015) 1842–1848]

    M. Hewitt, Y. Leblanc, Victor S. Gehling, Rishi G. Vaswani +18 more

    20151 citations

    Semantic Scholar

    Save

45. Abstract 1691: Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

    A. Moros, V. Rodríguez, I. Saborit-Villarroya, A. Montraveta +8 more

    20141 citations

    Semantic Scholar

    Save

46. Activity of DEM301, a novel anti-DEM-TXX antibody-drug conjugate for the treatment of gastrointestinal tumors.

    Sarah E. Carden, A. Denslow, Carmen Adriaens, P. Sandy +2 more

    2026Journal of Clinical Oncology0 citations Open access

    Semantic Scholar

    Save

47. Editorial Expression of Concern: The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

    C. Wong, S. Laddha, L. Tang, E. Vosburgh +6 more

    2026Cell Death and Disease0 citations Open access

    Semantic Scholar

    Save

48. Abstract LB062: DEM301, a novel bifunctional ADC with potent immunomodulatory activity for potential use in difficult to treat colorectal malignancies

    A. Denslow, Sarah E. Carden, P. Sandy, Sandeep Kumar +1 more

    2026Cancer Research0 citations

    Semantic Scholar

    Save

49. Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I

    Lin Yuan, Meghana Kulkarni, Evan L. Chiswick, Cheryl Koh +10 more

    2026Bayesian modeling allows early inference of pharmacokinetic/pharmacodynamic relationship for a novel small molecule STING agonist in Phase I0 citations Open access

    Semantic Scholar

    Save

50. IS COMPLEMENTARY THERAPY THE SOLUTION TO HELP PATIENT COPE BETTER WITH PHANTOSMIA?

    Nicole Murphy, P. Sandy, Preeti Gumbhir, Kate Robertson +1 more

    2024International Journal of Particle Therapy0 citations Open access

    Semantic Scholar

    Save